Pfizer — How AI Is Helping Match Patients to Clinical Trials Faster
ENTITYPfizer is using AI to accelerate patient-to-trial matching, reducing time-to-enrollment and expanding access to experimental therapies. AI-driven matching addresses a critical bottleneck in clinical trial recruitment, where identifying eligible patients from electronic health records remains labor-intensive. Faster trial matching benefits patients by reducing latency to experimental treatment and helps sponsors maintain enrollment timelines. However, AI matching algorithms introduce new risks around selection bias, differential access based on EHR data quality, and potential for AI systems to systematically exclude underrepresented populations from trials.
Subscribe to read full wiki analysis
Full wiki content — including source provenance, contradiction tracking, related pages, and analyst notes — is available to Subscriber members.
View Plans & SubscribeNew users get a 7-day trial — no credit card required.